Cancer immunotherapy: A treatment for the masses

Science

Volumn 305, Issue 5681, 2004, Pages 200-205

  Blattman, Joseph N ^a   Greenberg, Philip D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; PATHOLOGY; TUMORS;

ANTITUMOR RESPONSES; MOLECULAR IMMUNOLOGY;

IMMUNOLOGY;

CD3 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TOLL LIKE RECEPTOR;

MEDICINE;

ADOPTIVE TRANSFER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; MEDICAL RESEARCH; NATURAL KILLER CELL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES;

HARNESS;

EID: 3042844293     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1100369     Document Type: Review

References (46)

1. P. Ehrlich, Ned. Tijdschr. Geneeskd. 5, 273 (1909).
2. M. Burnet, Br. Med. J. 5022, 779 (1957).
3. O. Stutman, Science 183, 534 (1974).
4. V. Shankaran et al., Nature 410, 1107 (2001).
5. G. P. Dunn, L. J. Old, R. D. Schreiber, Annu. Rev. Immunol. 22, 329 (2004).
6. L. Zhang et al., N. Engl. J. Med. 348, 203 (2003).
7. F. M. Marincola, E. M. Jaffee, D. J. Hicklin, S. Ferrone, Adv. Immunol. 74, 181 (2000).
8. V. Groh, J. Wu, C Yee, T. Spies, Nature 419, 734 (2002).
9. D. I. Gabritovich et al., Nature Med. 2, 1096 (1996).
10. T. Wang et al., Nature Med. 10, 48 (2004).
11. K. Staveley-O'Carroll et al., Proc. Natl. Acad. Sci. U.S.A. 95, 1178 (1998).
12. E. Y. Woo et al., J. Immunol. 168, 4272 (2002).
13. V. H. Engelhard, T. N. Bullock T. A. Colella, S. L. Sheasley, D. W. Mullins, Immunol. Rev. 188, 136 (2002).
14. P. P. Lee et al., Nature Med. 5, 677 (1999).
15. S. E. Street et al., J. Exp. Med. 199, 879 (2004).
16. S. A. Rosenberg et al., J. Natl. Cancer Inst. 85, 622 (1993).
17. M. Nieda et al., Blood 103, 383 (2004).
18. M. Wilhelm et al., Blood 102, 200 (2003).
19. F.J. Lejeune et al., Surg. Oncol. Clin. N. Am. 10, 821 (2001).
20. K. Takeda, T. Kaisho, S. Akira, Annu. Rev. Immunol. 21, 335 (2003).
21. L. Gorelik, R. A. Flavell, Nature Med. 7, 1118 (2001).
22. B. Homey, A. Muller, A. Zlotnik, Nature Rev. Immunol. 2, 175 (2002).
23. C. E. Marroquin et al., J. Immunother. 25, 278 (2002).
24. M. von Mehren, G. P. Adams, L. M. Weiner, Annu. Rev. Med. 54, 343 (2003).
25. R. Clynes, T. Towers, L. Presta, J. Ravetch, Nature Med. 6, 443 (2000).
26. P. Carter, Nature Rev. Cancer 1, 118 (2001).
27. J. H. Timmerman et al., Blood 99, 1517 (2002).
28. A. Y. Huang et al., Science 264, 961 (1994).
29. D. M. Pardoll, Nature Rev. Immunol. 2, 227 (2002).
30. V. Karanikas et al., J. Immunol. 171, 4898 (2003).
31. F. O. Nestle et al., Nature Med. 4, 328 (1998).
32. S. A. Rosenberg et al., Nature Med. 4, 321 (1998).
33. A. van Elsas et al., J. Exp. Med. 194, 481 (2001).
34. G. Q. Phan et al., Proc. Natl. Acad. Sci. U.S.A. 100, 8372 (2003).
35. F. S. Hodi et al., Proc. Natl. Acad. Sci. U.S.A. 100, 4712 (2003).
36. J. Shimizu, S. Yamazaki, S. Sakaguchi, J. Immunol. 163, 5211 (1999).
37. R. P. Sutmuller et al., J. Exp. Med. 194, 823 (2001).
38. R. Childs et al., N. Engl. J. Med. 343, 750 (2000).
39. E. A. Walter et al., N. Engl. J. Med. 333, 1038 (1995).
40. C. M. Rooney et al., Blood 92, 1549 (1998).
41. C. Yee et al., Proc Natl. Acad. Sci U.S.A. 99, 16168 (2002).
42. M. E. Dudley et al., Science 298, 850 (2002).
43. R. J. Brentjens et al., Nature Med. 9, 279 (2003).
44. L. E. Cheng, C. Ohlen, B. H. Nelson, P. D. Greenberg, Proc. Natl. Acad. Sci. U.S.A. 99, 3001 (2002).
45. W. Y. Ho, J. N. Blattman, M. L. Dossett, C. Yee, P. D. Greenberg, Cancer Cell 3, 431 (2003).
46. J.N.B. is a fellow of the Cancer Research Institute. P.D.G. is a member of the Scientific Advisory Boards of Innate Pharma and Cerus Corporation.